R
Richard D. Carvajal
Researcher at Columbia University
Publications - 332
Citations - 28287
Richard D. Carvajal is an academic researcher from Columbia University. The author has contributed to research in topics: Melanoma & Medicine. The author has an hindex of 54, co-authored 282 publications receiving 23524 citations. Previous affiliations of Richard D. Carvajal include Cornell University & Kettering University.
Papers
More filters
Journal ArticleDOI
Proceedings of the Association for Research in Vision and Ophthalmology and Champalimaud Foundation Ocular Oncogenesis and Oncology Conference
Justine R. Smith,Jacob Pe'er,Rubens N. Belfort,Fatima Cardoso,Richard D. Carvajal,Carlos Carvalho,Sarah E. Coupland,Laurence Desjardins,Jasmine H. Francis,Brenda L. Gallie,Dan S. Gombos,Hans E. Grossniklaus,Steffen Heegaard,Martine J. Jager,Swathi Kaliki,Bruce R. Ksander,Markus Maeurer,Eduardo Moreno,Jose S. Pulido,Bettina Ryll,Arun D. Singh,Junyang Zhao,António Parreira,David J. Wilson,Joan M. O'Brien +24 more
TL;DR: The scientific program of the conference covered a broad range of ocular tumors—including uveal melanoma, retinoblastoma, ocular surface tumors, and adnexal and intraocular lymphomas—and pathogenesis and management were deliberated in the context of the broader systemic cancer discipline.
Journal ArticleDOI
Co-primary endpoint of overall survival for tebentafusp (tebe)-induced rash in a phase 3 randomized trial comparing tebe versus investigator’s choice (IC) in first-line metastatic uveal melanoma.
Jessica C. Hassel,Piotr Rutkowski,Jean-François Baurain,Marcus O. Butler,Max Schlaak,Ryan J. Sullivan,Sebastian Ochsenreither,Reinhard Dummer,John M. Kirkwood,Anthony M. Joshua,Joseph J. Sacco,Alexander N. Shoushtari,Marlana Orloff,Richard D. Carvajal,Omid Hamid,Shaad Essa Abdullah,Christopher J. Holland,Howard Goodall,Paul C. Nathan,Sophie Piperno-Neumann +19 more
TL;DR: Week 1 rash, presumed due to tebe redirection of T cells to gp100+ skin melanocytes, was associated with a very strong OS benefit, suggesting rash may be a marker that the immune system can be mobilized by tebe to target gp100-expressing melanocytes.
Journal ArticleDOI
First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors
Todd M. Bauer,Byong Chul Cho,Rebecca S. Heist,Lyudmila Bazhenova,Theresa L. Werner,Sanjay Goel,Dong-Wan Kim,Douglas Adkins,Richard D. Carvajal,Ajjai Alva,Keith D. Eaton,Judy Wang,Yong Liu,Xiao Qiang Yan,Jamie Christensen,Saskia T. C. Neuteboom,Richard C. Chao,Shubham Pant +17 more
TL;DR: Sitravatinib (MGCD516) as discussed by the authors is a spectrum-selective receptor tyrosine kinase inhibitor targeting TAM (TYRO3, AXL, MERTK) and split kinase family receptors, has demonstrated preclinical anti-tumor activity and modulation of tumor microenvironment.
Journal ArticleDOI
Clinical Utilization, Utility, and Reimbursement for Expanded Genomic Panel Testing in Adult Oncology
Susan J. Hsiao,Anthony N. Sireci,Danielle Pendrick,Christopher E. Freeman,Helen Fernandes,Gary K. Schwartz,Brian S. Henick,Mahesh Mansukhani,Kevin A. Roth,Richard D. Carvajal,Jennifer A. Oberg +10 more
TL;DR: The routine use of large next-generation sequencing pan-cancer panels is required to identify the increasing number of, but often uncommon, actionable alterations to guide therapy.
Journal ArticleDOI
A Phase Ib Study of Sotrastaurin, a PKC Inhibitor, and Alpelisib, a PI3Kα Inhibitor, in Patients with Metastatic Uveal Melanoma
Alexander N. Shoushtari,Shaheer Khan,Kimberly M. Komatsubara,Lynn G. Feun,Nicolas Acquavella,Shahnaz Singh-Kandah,Tiffany Negri,Alexandra Nesson,Kelly Abbate,Serge Cremers,Elgilda Musi,Grazia Ambrosini,Shing Lee,Gary K. Schwartz,Richard D. Carvajal +14 more
TL;DR: In this paper, a phase Ib study of sotrastaurin in combination with the PI3Kα inhibitor alpelisib was conducted to identify a tolerable regimen that may enhance the activity of PKC inhibition alone.